INR 1403.5
(0.25%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 106.61 Billion INR | 21.46% |
2022 | 87.77 Billion INR | 12.05% |
2021 | 78.33 Billion INR | 20.59% |
2020 | 64.96 Billion INR | 58.98% |
2019 | 40.86 Billion INR | 15.96% |
2018 | 35.23 Billion INR | 20.28% |
2017 | 29.29 Billion INR | 18.42% |
2016 | 24.73 Billion INR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | - INR | -100.0% |
2024 Q2 | 108.66 Billion INR | 0.0% |
2023 Q3 | - INR | -100.0% |
2023 FY | 106.61 Billion INR | 21.46% |
2023 Q2 | 102.92 Billion INR | 0.0% |
2023 Q1 | - INR | -100.0% |
2023 Q4 | 106.61 Billion INR | 0.0% |
2022 Q1 | - INR | -100.0% |
2022 Q2 | 86.21 Billion INR | 0.0% |
2022 Q4 | 87.77 Billion INR | 0.0% |
2022 FY | 87.77 Billion INR | 12.05% |
2022 Q3 | - INR | -100.0% |
2021 Q1 | - INR | -100.0% |
2021 FY | 78.33 Billion INR | 20.59% |
2021 Q3 | - INR | -100.0% |
2021 Q2 | 73.97 Billion INR | 0.0% |
2021 Q4 | 78.33 Billion INR | 0.0% |
2020 Q4 | 64.96 Billion INR | 0.0% |
2020 Q1 | 46.91 Billion INR | 14.81% |
2020 FY | 64.96 Billion INR | 58.98% |
2019 FY | 40.86 Billion INR | 15.96% |
2019 Q4 | 40.86 Billion INR | 0.0% |
2019 Q1 | - INR | 0.0% |
2018 FY | 35.23 Billion INR | 20.28% |
2017 FY | 29.29 Billion INR | 18.42% |
2016 FY | 24.73 Billion INR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Abbott India Limited | 51.93 Billion INR | -105.281% |
Cipla Limited | 327.17 Billion INR | 67.415% |
GlaxoSmithKline Pharmaceuticals Limited | 35.73 Billion INR | -198.321% |
Kopran Limited | 7.43 Billion INR | -1334.416% |
Marksans Pharma Limited | 26.8 Billion INR | -297.666% |
NGL Fine-Chem Limited | 3.55 Billion INR | -2898.642% |
Pfizer Limited | 42.28 Billion INR | -152.112% |
Sanofi India Limited | 17.14 Billion INR | -521.72% |
SMS Pharmaceuticals Limited | 10.34 Billion INR | -930.976% |
TTK Healthcare Limited | 12 Billion INR | -787.997% |